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Immune-based assays are promising tools to help to formu-
late diagnosis of active tuberculosis. A multiparameter ﬂow
cytometry assay assessing T-cell responses speciﬁc to Myco-
bacterium tuberculosis and the combination of both CD4
and CD8 T-cell responses accurately discriminated between
active tuberculosis and latent infection.
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Tuberculosis represents a major public health threat with >1.5
million deaths annually. Despite intensive investigations, rapid
formulation of diagnosis of active tuberculosis remains a
major obstacle to the global control of tuberculosis disease
[1]. The recent development of multiplexed assays in proteo-
mics, transcriptomics, or metabolomics may provide the basis
for developing highly sensitive and speciﬁc tools for active
tuberculosis diagnosis [2, 3]. In addition to molecular biology
assays, recent observations have indicated that immunological
measures may be instrumental in the diagnosis of active tuber-
culosis. We have recently shown using ﬂow cytometry that the
cytokine proﬁle of Mycobacterium tuberculosis (Mtb)-speciﬁc
CD4 T cells allowed a strong immunological discrimination
between patients with active tuberculosis and latentMtb infection
(LTBI) [4]. Furthermore, consistent with a previous study [5], we
recently conﬁrmed that Mtb-speciﬁc CD8 T-cell responses were
predominantly (>70%) found in patients with active tuberculosis
compared to those with LTBI (15%) [6]. On the basis of these
previous observations, we hypothesized that the combined as-
sessment of Mtb-speciﬁc CD4 and CD8 T-cell responses could
result in improved diagnosis of active tuberculosis.
To test our working hypothesis, we analyzed both the func-
tional proﬁle of Mtb-speciﬁc CD4 T-cell responses and the
presence of Mtb-speciﬁc CD8 T-cell responses in 194 subjects
diagnosed with active tuberculosis or LTBI, and performed
multivariate regression analysis to assess their relative or com-
bined capacity to distinguish active tuberculosis from latent
infection.
The results show that both individual immunological mea-
sures had variable power to discriminate between active tuber-
culosis and LTBI. However, the combination of both measures
greatly improved the power of this ﬂow cytometry–based assay
in the diagnosis of active tuberculosis.
METHODS
Study Groups
Of 53 patients with active tuberculosis, 28 have already been de-
scribed (Supplementary Table 1). Thirty had a diagnosis based
on laboratory isolation of Mtb on mycobacterial culture from
sputum, bronchoalveolar lavage ﬂuid, or biopsies and/or tuber-
culin skin test, enzyme-linked immunospot assay (ELISpot),
and/or polymerase chain reaction as described elsewhere [4].
Five patients (clinical tuberculosis, culture negative) presented
speciﬁc symptoms and radiological evidence of lesions sugges-
tive of tuberculosis and responded to treatment, and 16 patients
had a diagnosis based on GeneXpert assay (Supplementary
Table 1). All 141 LTBI subjects were previously described [4,
6] and were asymptomatic and had T-cell responses speciﬁc
to ESAT-6 and/or CFP-10 (detected by ELISpot and/or by in-
tracellular cytokine staining [ICS]). Subjects with LTBI were ei-
ther healthcare workers routinely screened at the Centre
Hospitalier Universitaire Vaudois (CHUV) or were investigated
Received 17 March 2013; accepted 1 October 2014; electronically published 31 October 2014.
Correspondence: Giuseppe Pantaleo, MD, Division of Immunology and Allergy, Lausanne
University Hospital, 1011 Lausanne, Switzerland (giuseppe.pantaleo@chuv.ch).
Clinical Infectious Diseases® 2015;60(3):432–7
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases
Society of America. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the work
properly cited. For commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/cid/ciu795
432 • CID 2015:60 (1 February) • BRIEF REPORT
for Mtb infection prior to the initiation of anti–tumor necrosis
factor alpha (TNF-α) antibody treatment and had chest radio-
graphs negative for lung lesions. Samples from active tuberculo-
sis patients and LTBI subjects were consistently and similarly
obtained, processed, stored, and analyzed. These studies were
approved by the institutional review board of the CHUV (num-
ber 35/09), and all subjects gave written informed consent.
Flow Cytometry Analyses and T-Cell Stimulations
In brief, cryopreserved peripheral blood mononuclear cells were
thawed, rested, and stimulated overnight with pools of overlap-
ping peptides encompassing ESAT-6 or CFP-10 and were then
labeled (viability dye, CD3, CD4, CD8, interferon gamma [IFN-
γ], TNF-α, and interleukin 2 [IL-2]), acquired on a 4-laser ﬂow-
cytometer and analyzed as described [4].
Statistical Analyses
Comparisons of categorical variables were performed using
Fisher exact test. Statistical signiﬁcance of the magnitude of
ICS responses was calculated by unpaired 2-tailed Student
t test using GraphPad Prism version 6. Logistic regression fol-
lowed by receiver operating characteristic (ROC) curve analysis
was used to evaluate the performances of each parameter (pres-
ence of Mtb-speciﬁc CD8T cells and the frequency of single
TNF-α–producing CD4 T cells) to identify active tuberculosis
[7]. A linear logistic regression model was used to assess the po-
tential beneﬁt of the combination of both covariates. This
model estimated the log odds of active tuberculosis disease
probability as a function of both variables. Results for the dis-
tinct variables were summarized as a contingency table giving
sensitivity, speciﬁcity, positive predictive value (PPV), and neg-
ative predictive value (NPV). These analyses were performed
using MedCalc 13.3.3 and was conﬁrmed using R-Cran associ-
ated with the “pROC” and “ROC” packages in addition to in-
house coding.
RESULTS
We enrolled 141 patients with LTBI and 53 patients with un-
treated active tuberculosis (Supplementary Table 1). Mtb-
speciﬁc CD4 and CD8 T-cell responses were assessed using
polychromatic ﬂow cytometry following stimulation with
ESAT-6 and CFP-10 peptide pools and labeled with a viability
marker and anti-CD3, -CD4, -CD8, -IFN-γ, -TNF-α, and -IL-2
antibodies as described [4].
Functional Proﬁle of Mtb-Speciﬁc CD4 T-Cell Responses and
Identiﬁcation of Mtb-Speciﬁc CD8T Cells in Patients With Active
or Latent Tuberculosis
Consistent with our previous observation [4], the cytokine
proﬁle of Mtb-speciﬁc CD4 T-cell response was distinct
between active tuberculosis patients and LTBI subjects, and a
signiﬁcantly (P < .00001) higher proportion of single TNF-α–
producing CD4 T cells was found in patients with active tuber-
culosis (Figure 1A).
Furthermore, as previously shown [5, 6], Mtb-speciﬁc CD8
T-cell responses were detected in the majority of active tubercu-
losis patients (69.8%) and in few (15%) LTBI subjects (P < .0001;
Figure 1B). In contrast, the magnitude of Mtb-speciﬁc CD8
T-cell responses, as determined by the frequency of IFN-γ–
producing CD8 T cells, was not signiﬁcantly different between
LTBI and active tuberculosis subjects (Figure 1C).
Potency of the Individual Immunological Measures in the
Diagnosis of Active Tuberculosis
We then calculated the capacity for each parameter (ie, the cy-
tokine proﬁle of Mtb-speciﬁc CD4 T cells or the detection of
Mtb-speciﬁc CD8 T-cell responses) to distinguish active tuber-
culosis patients from LTBI subjects.
On the basis of a logistic regression analysis, we conﬁrmed
that the cytokine proﬁle of Mtb-speciﬁc CD4 T cells was a
strong predictor of active tuberculosis or latent infection (area
under the curve [AUC] = 0.79 [95% conﬁdence interval {CI},
.72–.84]; Figure 2A). Using the predeﬁned threshold of
37.4% of single TNF-α–producing CD4 cells [4], the odds
ratio (OR) was 17.7, the speciﬁcity was 93.6%, the sensiti-
vity was 60.4%, and PPV and NPV were 76.3% and 84.6%,
respectively.
The detection of Mtb-speciﬁc CD8 T cells was also a strong
predictor of discrimination between active and latent tuberculo-
sis, although it was less accurate than the CD4 T-cell cytokine
proﬁle (AUC = 0.77 [95% CI, .71–.83]; OR = 13.1; speciﬁcity =
85%; sensitivity = 69.8%; PPV = 63.8%; NPV = 88.1%; Figure 2B).
Combination of Mtb-Speciﬁc CD4 and CD8 T-Cell Responses to
Diagnose Active Tuberculosis
We then combined both components of the Mtb-speciﬁc T-cell
response (ie, the cytokine proﬁle of Mtb-speciﬁc CD4 T cells
and the detection of Mtb-speciﬁc CD8 T-cell responses). A lo-
gistic regression model was used to assess the potential beneﬁt
of the combination of both covariates. This model estimated the
log odds of active tuberculosis probability as a function of both
variables, identifying a new covariate, termed “SCORE,” which
was deﬁned as follows:
Log (odds) ¼ SCORE  0:071  ½%TNFa þ 2:6  ½CD8:
where %TNF-α refers to the percentage of Mtb-speciﬁc single
TNF-α–producing CD4 T cells and CD8 refers to 0 (zero) or
1 according to the absence or presence of an Mtb-speciﬁc
CD8 T-cell response, respectively (P < .0001 for both coefﬁ-
cients). With an AUC of 0.89 (95% CI, .83–.93; Figure 2C),
the SCORE was a signiﬁcantly improved predictor measure of
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discrimination between active and latent tuberculosis compared
with both individual variables analyzed independently (both
P < .004). Analysis of the distribution of SCORE results from tu-
berculosis and LTBI subjects showed a signiﬁcant difference be-
tween the groups (P < .0001; Figure 2D). On the basis of the
logistic regression analysis, an optimal cutoff of SCORE of 3
was determined (Figure 2D), and assay performances were as
follows: OR = 26.2, speciﬁcity = 86.5%, sensitivity = 81.1%,
PPV = 66.7%, and NPV = 93%. Compared with the individual
use of the percentage of single TNF-α–producing CD4 T cells,
the combined use of CD4 and CD8 T-cell responses was associ-
ated with substantial improvement in the NPV (10% increase),
PPV (10% increase), OR (48% increase), and sensitivity (34%
increase) but a minor decrease in speciﬁcity (7%).
Figure 1. Mycobacterium tuberculosis (Mtb)-speciﬁc CD4 and CD8 T-cell responses. A, Analysis of the functional proﬁle of Mtb-speciﬁc CD4 T cells on
the basis of interferon gamma (IFN-γ), interleukin 2 (IL-2), and/or tumor necrosis factor alpha (TNF-α) production. All 194 individuals hadMtb-speciﬁc CD4 T-
cell responses, and 216 and 73Mtb-speciﬁc CD4 T-cell responses against ESAT-6 or CFP-10 were analyzed in the 141 patients with latent tuberculosis (LTBI)
and 53 patients with tuberculosis (TB), respectively. The combinations of the different functions are shown on the x-axis, and the percentages of the distinct
cytokine-producing cell subsets within Mtb-speciﬁc CD4 T cells are shown on the y axis. The pie charts summarize the data. Comparisons of marker dis-
tribution were performed using Student t test and a partial permutation test as described elsewhere [8]. B, Proportion of LTBI subjects and TB patients with
detectable Mtb-speciﬁc CD8 T-cell responses. Mtb-speciﬁc CD8 T-cell responses were deﬁned by the presence of IFN-γ–producing CD8+CD4–CD3+ T cells
following stimulation with ESAT-6 and/or CFP-10 peptide pools. Statistical signiﬁcance was calculated using 2-tailed Fisher exact test. C, Magnitude (mean
with 95% conﬁdence interval) of Mtb-speciﬁc CD8 T-cell responses (against ESAT-6 and/or CFP-10) in the 21 LTBI and 37 TB patients with detectable Mtb-
speciﬁc CD8 T-cell responses. An unpaired 2-tailed Student t test was performed.
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Of interest, assay performance was not signiﬁcantly different
between culture-positive tuberculosis and culture-negative tu-
berculosis or by tuberculosis clinical status (pulmonary vs ex-
trapulmonary tuberculosis; Supplementary Figure 1), nor by
the geographical origin of participants.
DISCUSSION
Cellular immune responses are involved in the control of Mtb
infection [9], and both CD4 and CD8 T cells play a key role
in granuloma formation [10]. As opposed to CD4 T cells, the
function of Mtb-speciﬁc CD8 T cells remains unclear, even
though they were described in humans as well as in animal
models [6, 11–13] and were associated with the pathogen load
[14] or with better disease control [15].
T-cell–based assays such as IFN-γ release assays have sub-
stantially improved the diagnosis of Mtb infection but have
failed to discriminate between active and latent tuberculosis
[16, 17]. Recently, the functional proﬁle of Mtb-speciﬁc CD4
T cells has shown to be instrumental in discriminating between
patients with LTBI and those with tuberculosis [4].
It was previously shown that Mtb-speciﬁc CD8 T-cell re-
sponses are generated in response to high bacillary load and
may be able to distinguish children with active tuberculosis
from LTBI [14]. Here, we demonstrate that the detection of CD8
T-cell responses can discriminate between active tuberculosis
Figure 2. Individual and combined performances of the distinct components of the Mycobacterium tuberculosis (Mtb)–speciﬁc T-cell response to diag-
nose active tuberculosis (TB). A, Logistic regression analysis showing the association between the proportion of single tumor necrosis factor alpha (TNF-α)–
producing CD4 T cells with the ability to discriminate between active TB and latent Mtb infection (LTBI) (area under the curve [AUC] = 0.79 [95% conﬁdence
interval {CI}, .72–.84]). B, Logistic regression analysis showing the association between the presence of a detectable Mtb-speciﬁc CD8 T-cell response with
the ability to discriminate between active TB and LTBI (AUC = 0.77 [95% CI, .71–.83]). C, Logistic regression analysis showing the association between the
SCORE (integrated combination of the proportion of single TNF-α–producing CD4 T cells and the presence of a detectable Mtb-speciﬁc CD8 T-cell response)
with the ability to discriminate between active TB and LTBI (AUC = 0.89 [95% CI, .83–.93]). D, Analysis of the distribution of SCORE results on the 141 LTBI
subjects and the 53 active TB patients from this study.
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and LTBI also in adults, but is substantially less powerful than
the Mtb-speciﬁc CD4 T-cell response (ie, single TNF-α–
producing CD4 T cells). More importantly, the multivariate
analysis combining both the functional proﬁle of CD4 T cells
and the presence of Mtb-speciﬁc CD8 T cells led to the identiﬁ-
cation of a new variable (SCORE) and to a signiﬁcantly improved
discrimination between patients with active vs latent tuberculosis.
The 2 immunological measures, that is, increase in the per-
centage of singleMtb-speciﬁcTNF-α–producingCD4Tcells and
the detection ofMtb-speciﬁc CD8 T cells, when used in combi-
nation have a sensitivity (81.1%) and a speciﬁcity (86.5%) in
the same range of other immunological assays measuring only
IFN-γ such as the T.SPOT.TB and the QuantiFERON-TB Gold
In-Tube test while largely superior to the tuberculin skin test
[18]. However, the present ﬂow cytometry–based assay has
the advantage of discriminating between active and latent tuber-
culosis, which is not the case for the 2 assays measuring only
Mtb-speciﬁc T cells producing IFN-γ. In this regard, recent
studies have identiﬁed other immunological markers that may
discriminate between active and latent tuberculosis. The new
markers include IFN-γ and IL-2 single T-cell responses [19]
and the decrease of CD27 expression in Mtb-speciﬁc CD4
T cells [20]. However, the former markers were analyzed in a
very small number (<20) of patients, and the latter has been
shown to discriminate between active and chronic tuberculosis
only in pediatric patients [21] and to be associated with persistent
active tuberculosis in adult patients [22]. Therefore, the ﬂow
cytometry–based assay and the combined use of the 2 immuno-
logical measures described in the present study represent the
most instrumental tool for discriminating between active and
latent tuberculosis in adult patient populations.
The sensitivity of immunologically based assays in discrimi-
nating between active and latent tuberculosis is inferior to that
of molecular assays such as the Xpert MTB/RIF test, which is
based on DNA ampliﬁcation and has a sensitivity of 99.8% in
smear-positive and culture-positive cases and 90.2% in smear-
negative and culture-positive cases. However, the limitation of
this test is that it can be performed only on sputum samples,
which are difﬁcult to collect in children.
With regard to the feasibility of implementing this technolo-
gy in developing countries with high tuberculosis prevalence,
the antibody panel to measure these Mtb-speciﬁc CD4 and
CD8 T-cell responses has been validated in our laboratory for di-
agnostic use and routinely performed on a Facscanto ﬂow cytom-
eter at the Lausanne University Hospital. The implementation of
the present test in laboratories in developing countries is certainly
feasible if the appropriate ﬂow cytometry equipment is available.
However, the assay is currently performed on blood mononuclear
cell preparations, and the possibility of performing the assay on
total blood will facilitate substantially the implementation of the
test in laboratories in developing countries.
In conclusion, the present ﬂow cytometry–based assay and
the combination of 2 immunological measures—Mtb-speciﬁc
CD4 T cells producing TNF-α and the detection ofMtb-speciﬁc
CD8 T-cell responses—represent a powerful diagnostic tool to
discriminate between active tuberculosis and latent infection.
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